Randox Food Diagnostics harnessing science of antibiotic screening to ensure safer honey
Global leader in food screening technology, Randox Food Diagnostics have developed a range of pioneering honey quality tests which are being adopted by apiculturists across the world to ensure the safety and quality of their produce.
The array of tests, developed by the Antrim-based firm, are being showcased this week at the world’s largest apiculture meeting, the Apimondia International Conference, being held in Istanbul, Turkey from September 29th to October 4th.
The company hopes to highlight to consumers and producers about the importance of food safety, and in particular the dangers of antibacterial residue in food. Scientists have warned that antibiotics used in food production, are passing through the food chain to consumers and therefore contributing to the rise in infections caused by antibiotic-resistant bacteria.
Randox Founder and Managing Director, Dr Peter FitzGerald, commented;
“As a company committed to supporting the fight against antibiotic resistance we must continue to drive awareness amongst producers and consumers alike.
“We are working closely with industry to promote a responsible approach to antibiotic use in food production and we hope that by working with some of the biggest names in the apiculture market, other honey producers will see the benefits of being able to offer their customers complete consumer confidence in a high quality, and importantly, safe product.”
At Apimondia 2017 Randox Food Diagnostics will showcase a range of major technological advancements including the firm’s Antimicrobial Array 1 Ultra, Antimicrobial Array II Plus and Antimicrobial Array V. Thanks to Randox’s patented Biochip Array Technology, these testing panels can simultaneously screen for multiple antibiotics that are sprayed on beehives to ensure the safety of the colony, from only one sample of the produce.
Randox Food’s Antimicrobial Arrays join the company’s already extensive menu of honey screening tests, including its test for Hydroxymethylfurfural (HMF), a test for an organic compound produced by dehydration of sugars, which can be indicative of overheating, poor storage conditions or aged honey. The test was recently validated by leading South American honey producer Geomiel, which credited Randox Food for delivering an immediate improvement in the quality of its honey products.
David Ferguson, Global Business Manager for Randox Food Diagnostics, commented;
“We welcome the fact that so many of the world’s leading producers, including Geomiel, have embraced our vision of continuously improving testing standards.
“We have invested a lot in simplifying the process of conducting multiple tests, and consolidating this onto one unique biochip is a cost-effective way for the honey industry to maintain and improve standards. Apimondia 2017 attendees will be offered a complete testing bundle – including our popular analysers, the Randox Evidence Investigator and RX misano, to enable them to test for antibiotics and assess quality in one easy-to-manage system.
“Another unique feature of what we offer here at Randox Food Diagnostics is our ever-expanding test menu. The RX misano for example has a customisable test menu which allows clients to upload new parameters using USB, ensuring access to the most up-to-date tests on the market.
“We will be inviting Apimondia guests to learn more about the upcoming launch of our new pesticide tests, which will provide multiple results for the world’s most prevalent pesticides, such as Amitraz, Acetamiprid, Carbofuran, Carbaryl, and Paraquar. We remain committed to supporting food producers by providing them with the newest and highest quality tests.”
For further information about Randox Food Diagnostics honey testing, please visit: http://www.randoxfood.com/Matrices/Honey
For any further questions please contact Randox PR by phoning 028 9445 1016 or emailing RandoxPR@randox.com
Join us as we celebrate World Heart Day on the 29th of September 2017. Randox Reagents aim to make a difference around the world and inspire millions to be heart healthy through offering a wide range of cutting edge cardiology and lipid reagents.
Cardiovascular disease (CVD) is responsible for 17.5million deaths per year worldwide, making it the leading cause of death (WHO, 2015). This figure is predicted to rise to 23.6million by 2030, emphasising the need for further risk assessment biomarkers to be taken into account in the assessment of CVD.
Some of our most unique cardiac assessment reagents include:
HDL3 is our most recent addition to our cardiology testing panel. HDL3 is a sub-fraction of the HDL molecule, and enhances risk profiling of CVD due to its strong correlation with MI; elevated levels of HDL3 particles reflect abnormally increased triglyceride content of the HDL particle. This means that whilst a patient may have high levels of HDL, they may also have elevated levels of HDL3 which essentially renders the potentially potent protection factor of HDL as a cholesterol scavenger as almost useless.
Randox offers an automated HDL3 assay for the quantitative determination of HDL3 cholesterol in human serum or plasma. For more information, click here.
sLDL is a subtype of LDL Cholesterol. It is more atherogenic due to its small size which makes it more susceptible to oxidation, and enables it to more readily permeate the inner arterial walls, causing damage and destruction. As such, the measurement of sLDL is extremely valuable as a vital risk marker of MI; in fact, elevated levels of sLDL are associated with a three-fold increased risk of MI.
Randox offers an automated sLDL assay with a wide measuring range of 0.189-22.2 mmol/l; therefore it will comfortably detect levels outside of the healthy limit of 4.90 mmol/l, ensuring a worthy addition for true assessment of CVD risk. For more information, click here.
Lp(a) offers an excellent addition to the lipids profile, and should be considered due to its role in the assessment of genetically inherited risks of CVD. As genetically determined, Lp(a) remains fairly constant and is unaffected by lifestyle changes and some treatments. Elevated levels are associated with premature development of atherosclerosis and CVD, and are independent of other lipids. Testing for elevated levels is recommended for patients with a family history of premature CVD or elevated Lp(a), and for patients who have developed CVD at a young age.
Randox Lp(a) offers superior methodology, as it contains a very high density of isoform-insensitive antibodies and detection reagent. There is a five point calibrator available which takes into account the heterogeneity of the Lp(a) molecule for each of the levels, which results in excellent commutability of the calibrator with patient samples. For more information, click here.
You can download our cardiology & lipid testing brochure for a full list of our specialised reagents!
For more information, please contact us at firstname.lastname@example.org
As the supplier of a pioneering diagnostic able to assist with differentiating between coronary pain and non-cardiac chest pain, Randox Laboratories has this week welcomed news about the importance of introducing new innovations which can significantly improve patient outcomes.
Prioritising people presenting with a heart attack over those with non-cardiac chest pain is one of the biggest challenges A&E doctors face – there are around 200,000 heart attacks each year in the UK, but around 1 million people come to A&E with chest pains. According to a team from King’s College London, as reported by the BBC, a faster, more accurate diagnosis of whether chest pain is caused by a heart attack would save the health service millions of pounds each year by sending well patients home and freeing up beds. Yet current testing methods do not efficiently differentiate between high-risk patients and the estimated 80% of patients who are not having a heart attack.
Randox’s revolutionary test for Heart-Type Fatty Acid-Binding Protein (H-FABP) however, when combined with current testing, is able to rule out a heart attack for patients who present at A&E with chest pain which is caused by other conditions such as respiratory issues, meaning they may not need emergency admission.
When measured at the time a patient presents to A&E with chest pain, H-FABP enables doctors to triage patients suffering with a heart attack more efficiently than before.
Dr. Gary Smyth, Medical Director at Randox Laboratories, hopes that more efficient testing will become widely available so that doctors can identify and prioritise patients at risk;
“Despite the best efforts of our NHS colleagues, EDs across the UK are under tremendous pressure. In many cases people are presenting with chest pain but aren’t suffering from a heart attack, and given that current cardiac tests are not as sensitive as clinicians would like, these patients are being admitted unnecessarily, taking up beds and valuable resources.
“It is imperative that newer, faster tests are adopted because fundamentally this means saving lives.”
H-FABP is released into the bloodstream within 30 minutes of a heart attack, whereas people who are currently admitted to hospital with chest pains may have to wait several hours for test results. Even the latest heart attack test to be adopted by the NHS, troponin, can take up to six hours to provide confirmation.
H-FABP, conversely, is released from the heart during the early stages of a heart attack and because it is so small, it can be detected when the heart cells are being damaged, rather than at the stage when troponin would usually be detected – when cell death has already occurred. The test can also be used to identify people who are at high risk of heart attack in the near future.
Dr. Peter FitzGerald, Founder and Managing Director of Randox Laboratories, commented;
“Research shows that patients who were troponin negative and therefore sent home from hospital, but who were positive for H-FABP, were at high risk of death – as high as a 20% chance of death that same year.
“If the H-FABP test was added to existing tests upon arrival at hospital, doctors could quickly and accurately rule out the 80% of chest pain patients who are not having a heart attack, allowing resources to be focused on those who are actually at high risk.”
World Heart Day – 29th September – Introduction
This year (29th September 2017) join us as we help to raise awareness for World Heart Day! The theme for this year’s World Heart Day is to share the power – and you know what they say… “Knowledge is Power” so throughout this blog we will be providing vital knowledge as well as tips to having a healthy heart!
The heart is a muscular organ that pumps blood around the body and is indeed central to your circulatory system. The system consists of a network of blood vessels, including, veins, arteries and capillaries. These vessels transport blood – as well as carrying oxygen and other important nutrients – to every part of the body. Ensuring a healthy heart is therefore vital.
What is CVD?
When too much pressure is put on our hearts we start to run into some issues – the general term for conditions affecting the heart is Cardiovascular Disease – better known as CVD. The exact cause of CVD is far from clear, with many factors increasing your chances of developing CVD. These risk factors can include, but are not limited to, high blood pressure, smoking, high cholesterol, being overweight or in many cases, can be hereditary.
It is important to note that Cardiovascular Disease is accountable for nearly half of all non-communicable disease (NCD) deaths, therefore making it the number one killer across the globe! Scary thought considering there are a whopping 17.3 million CVD related deaths per year – including stroke and heart disease. Understanding CVD in today’s society is more important than ever before, we need to know the truth about CVD and be able to decipher the facts from the fiction. Below you can see a few examples of common misconceptions regarding CVD and also some that are indeed true.
Only older men can get heart disease/CVD
Cardiovascular Disease can develop before birth
Exercising won’t help if you’re genetically predisposed to CVD
Low and middle-income countries are the most susceptible to CVD
It is estimated that by 2030 the number of deaths, due to CVD, will rise to an enormous 23 million globally! However, by raising awareness of the critical numbers and facts we can all help prevent CVD by making small, simple lifestyle changes.
Tips for a Healthy Heart
Using our “art into heart” graphic below, we decided to outline some of our Randox QC top tips for staying healthy! Why not try some of them and feel the effects of having a happy, healthy heart!
This World Heart Day, join us and many more around the world, to raise awareness for this great cause and unite together to “Share the Power”.
Ulster University’s GAA team is preparing to travel to China on an historic tour of the country as part of the university’s wider programme of engagement in key international markets.
The trip, which will be sponsored by Crumlin-based diagnostics firm Randox, will see a 35 strong team depart on 28 October for a two week cultural exchange that aims to develop and enhance links with a number of Chinese academic institutions.
The team will travel to Beijing, Wuhan, and Huangshi City and play several games as part of an extensive tour promoting sporting excellence at Ulster University and Gaelic Games in particular.
Professor Ian Montgomery, Pro-Vice Chancellor, Global Engagement at Ulster University said:
“GAA is of increasing interest to the Chinese people and there is a strong appetite to learn about the various sports, key tactics and the strong cultural identity which Ulster University’s GAA team has developed over many decades. This tour, supported by Randox, will give our team the opportunity to showcase Gaelic football and hurling to a vast audience which is interested to learn more and experience a game first-hand through a number of Gaelic Games masterclasses.”
“As an internationally focused university it is important to continually build new partnerships in this vast market and further enhance existing linkages. From research collaborations with some of China’s top universities to our role as home to the Confucius Institute and Confucius classrooms initiative in Northern Ireland, China remains a significant market with clear potential for growth. We look forward to building on our work in this region and meeting new connections as part of the tour.”
Dr Peter FitzGerald, founder of Randox, said:
“We are pleased to support Ulster University’s Gaelic team as they embark on a very exciting tour of China. It is one of our most important markets, as we have been exporting to China since 1992 and we have had an established presence in the region for several years. This is a brilliant opportunity for our partnership with Ulster University to profile some of the young sporting talents of Northern Ireland and to strengthen key business relationships in an important market.”
For further information about the Randox-sponsored GAA tour, please contact Randox PR by phoning 028 9445 1016 or emailing RandoxPR@randox.com
This week marks Urology Week, an important week in the annual health calendar. Urology Week is an initiative of the European Association of Urology (EAU) that aims to raise awareness of urological conditions among the general public and provide knowledge into how vital urology is to your standard of life.
What is Urology?
Urology is a surgical speciality which involves the diagnosis and treatment of disorders of the kidneys, ureters, bladder, prostate and male reproductive organs. It is an extremely varied branch of medicine and caters for patients of both genders and all ages, from infants to elderly pensioners. (1)
Did you know?
There are 25 million or 16% of Europeans above 40 years of age who experience some symptoms of urinary incontinence, with costs of this condition totalling approximately €7 billion in just 6 countries? Currently, 10% of all medical care involves Urology which is a large proportion of the annual healthcare spend. (2)
The RX series Clinical Chemistry Analysers offer a comprehensive renal testing panel which allows for a quick and accurate diagnosis to combat urological diseases.
The RX series Renal Function Test Panel is aimed to help diagnose and manage conditions affecting kidney function; these tests may be used as part of general health screening or to screen someone who is at risk of developing kidney disease.
Why choose the RX series analysers to test Renal Function?
- Extremely low patient sample volumes are required ensuring the upmost in patient comfort
- Accurate testing ensures patients can receive correct treatment as early as possible
- STAT functionality allows for the addition of emergency samples when required
- Advanced QC capabilities insuring your results are both accurate and reliable.
Follow us on Social Media
(1) The British Association of Urological Surgeons Limited. (2017). What Is Urology? Available: https://www.baus.org.uk/patients/information/default.aspx. Last accessed 26th Sept 2017.
(2) European Association of Urology. (2017). Urology Statistics.Available: http://www.urologyweek.org/what_is_urology/statistics/. Last accessed 26th Sept 2017.
What makes Randox the successful, innovative and forward-thinking company it is today are the passionate, hard-working and talented staff we’re lucky enough to call our colleagues.
Our staff are our best asset and across every division our team help to save lives – whether it be designing the newest Biochip to test for Alzheimer’s disease, developing the latest software for use in hospitals and universities, making food safer for people to eat, or managing our global offices, to ensure our pioneering health technologies make their way across the world to where they are needed the most.
Our headquarters are in Northern Ireland, but we have teams based all over the world, including in Portugal, where Cristina Zenha works as part of the Portuguese Finance Team.
2017 is a special year for Cristina. It marks 25 years since she began her job with Randox.
We sat down with Cristina to ask her about her time with us, to find out how she thinks the company has changed during that time, and of course to congratulate her on her exciting milestone!
Here’s Cristina’s story.
My name is Cristina Zenha and I work in the Finance team in Randox Portugal in Oporto.
For those of you who don’t know the area, the weather is very good here in Oporto. It’s not very cold in winter, nor is it very hot in summer. It’s just right! During the summer I love going to the Algarve for my holidays. There are beautiful beaches and the weather is excellent, so it’s a very popular holiday destination for both the Portuguese and for tourists.
In Portugal, Randox is based in Oporto City, which as one of the oldest tourist destinations in Europe, has a wonderful artistic heritage. The Port Wine, the vast spaces dedicated to leisure and culture, and the relaxed way of life are just some of the reasons I would recommend visiting the city!
We also have excellent cuisine here in Portugal. Seafood is very popular and we have several famous cod recipes. In Oporto specifically, we have a very famous dish called Francesinha, which is a Portuguese sandwich made with bread, ham, fresh sausage and steak, covered with melted cheese and a hot thick tomato and beer sauce, and served with french fries.
Before I moved into the world of full-time work I worked in my parents’ grocery store, which sparked my interest in business. Then I began my first serious job in Randox Portugal when I was only 19 years old, and studied part-time Business Management in Oporto Lusiada University. I took my university classes in the evening to work around my job with Randox.
When I had my interview I had a really good feeling about Randox. I could tell that this company, which was only just beginning to establish itself in Portugal, was going to go far. I could see myself developing both personally and professionally in what was evidently a globally successful organisation. I knew I would learn a lot.
When I started my job with Randox in Oporto I was involved in processing orders, documenting stock, and organising customer invoices and receipts. However in the 25 years I’ve worked here, my job, and the office itself have evolved and changed. My current responsibilities have progressed to additionally include office finances and accounts, and I also manage the logistics of our site.
How we work in the team has also changed drastically. I remember when I first started in 1992 there were no computers so everything was done manually. I had a typewriter to make invoices, receipts and letters. We created manual maps for everything and we updated everything manually.
The team itself has more than doubled in size, in spite of a number of economic crises in Portugal during that period. The infrastructure in Randox, and its offering of highly innovative diagnostics has meant that demand for our products has continued to increase. We have a fantastically passionate team in place who all want to see the business succeed and everyone works together to bring next-generation healthcare to hospitals and laboratories across Portugal.
I think that’s one of the reasons I love my job so much. Each member of the team here has an important role to play and we each contribute to Randox’s vision of saving lives. It’s fast-paced and challenging, but that’s what I love. I like the structure in place and I enjoy the satisfaction that comes with resolving issues and contributing to increased sales and overall business success. I can’t wait to see what the future holds for Randox. I know that the company will continue to grow and succeed and I feel privileged to be involved in its journey.
I want to say a big thank you to everyone with whom I have worked during my 25 years here at Randox. I love everyone I work with and you are such a big part of why I have loved my time here so much. I want to say a big thank you in particular to Bob Allan in Finance, who was one of the first people I met in Randox. He has always been on hand to support the work we do in the Portuguese office, and the way in which he made me feel so welcome and supported will always be one of my favourite memories of my first 25 years working in Randox.
Here’s to the next 25!
Congratulations Cristina on your 25 year milestone with us here at Randox. You are a real asset to our global healthcare company and we are delighted to have you as part of our team!
For more We Are Randox stories about our amazing colleagues, make sure to follow us on Facebook, Instagram and Twitter and follow the hashtag #WeAreRandox.
For current vacancies in our team, visit careers.randox.com
Global drug tests provider Randox Toxicology has today pledged its support for the PSNI in the fight against fentanyl, a strong painkiller which has been found for sale on the black market in Northern Ireland for the first time.
Fentanyl, which is an opioid pain medication currently classed as a controlled Class A drug under the Misuse of Drugs Act 1971, has been found in heroin which was seized by the PSNI, and has been linked to two deaths in Northern Ireland this year.
It is currently used to safely treat patients with severe pain, as it can be 50 to 100 times more potent than morphine. According to the National Crime Agency and Office for National Statistics however, 60 deaths in the UK in the past eight months have been attributed to misuse of fentanyl, which received international attention when the singer Prince was found to have died from a fentanyl overdose.
Dr. Peter FitzGerald, Founder and Managing Director of Randox Laboratories, commented;
“It is extremely worrying to hear that the PSNI have confirmed fentanyl has reached the black market in Northern Ireland. The illegal sale of the painkiller has long been an issue in the USA, with the country having at least two million opioid addicts, but until now has not been used illegally in NI.
“Fentanyl’s status as a painkiller is potentially why it is so commonly abused, as those using prescription painkillers may turn to illicit substances, such as fentanyl, when their prescriptions run out. With as little as 2mg able to cause an overdose, fentanyl is easily hidden and transported in small packages through the post, so poses a major danger to society. The drug has high abuse potential and is being used more and more by drug dealers who can sell fentanyl at a cheaper price than heroin.”
Randox Toxicology, a specialist division of FitzGerald’s Antrim-headquartered Randox Laboratories, has today issued a statement to pledge its commitment to removing the danger of fentanyl from Northern Ireland. The company’s significant investment in the research and development of new tests for drug detection has cemented its status at the forefront of the drugs screening industry. Randox Toxicology, which developed its first fentanyl test in 2007, has the world’s only tests for the designer opiates U-47700, MT-45 and AH-7921.
Dr. Joanne Darragh, Head of Research and Development at Randox Toxicology, commented;
“In the endless pursuit of creating innovative tests for new drugs which emerge weekly on to the market, our expertise at Randox Toxicology sets us apart from the rest of the industry. Not only have we been first to market with a number of opioid tests, but we have also developed our patented Biochip Array Technology, which enables us to simultaneously screen for both fentanyl and heroin, one of which may have been laced with the other.
“Today we pledge the support of our expertise, based on a decade’s worth of experience in developing fentanyl tests, to the PSNI in their efforts to remove the fentanyl threat from Northern Ireland. This is a problem that we must tackle together and we are confident that by highlighting this growing epidemic, we can educate communities on the devastating effects the misuse of fentanyl can have.”
For further information about Randox Toxicology’s fentanyl screrening please contact Randox PR on 028 9445 1016 or email RandoxPR@randox.com
During the second week of our adiponectin educational month, we begin to focus on the key features and benefits of Randox Adiponectin. Check back here every day to read about a different feature of our automated biochemistry reagent.
Read on to find out more!
A – Automated Biochemistry Assay
One of the most important features of Randox Adiponectin is that it is an automated biochemistry assay, removing the inconvenience and time consumption associated with traditional ELISA based testing. Moving from ELISA to automated methods also allows laboratories to expand their test offerings to patients and clinicians.
D – Decreased Serum Adiponectin Levels
Adiponectin is the most abundant protein secreted by adipose tissue and exhibits insulin-sensitising and anti-inflammatory properties, therefore decreased levels of serum adiponectin is an independent risk factor for progression to type 2 diabetes as well as being linked with other pathologies such as metabolic syndrome, cancer and cardiovascular disease.
I – Increase in Adiponectin Levels
An increase in adiponectin levels is inversely associated with progression to type 2 diabetes mellitus (T2DM) and subsequently, a reduced risk of cardiovascular events and several obesity-associated cancers. Adiponectin levels can be increased through diet, physical activity and the reduction of abdominal visceral fat.
P – Preventing and Treating Obesity Related Diseases
Studies have highlighted that adiponectin exhibits anti-inflammatory, anti-atherogenic and anti-diabetic properties, with various functions possibly serving to prevent and treat obesity-related diseases and cardiovascular disease.
O – You Don’t Have to be Overweight to be at Risk
It is widely recognised that people who are overweight are a higher risk of developing T2DM, metabolic syndrome, cardiovascular disease and cancer. This is commonly assessed through measuring Body Mass Index (BMI), however it has limitations and varies in reliability based on age, sex and race. Risk is more accurately identified through abdominal visceral fat (AVF) levels. Adiponectin levels have been shown to have a direct inverse correlation with AVF levels making adiponectin levels a much more reliable indicator of at-risk patients.
N – Niche Product from Randox
Randox automated Adiponectin is a niche product, meaning that we are one of the only manufacturers to supply this reagent in an automated biochemistry format. This is superior to traditional T2DM risk assessment methods.
E – Extensive Measuring Range
Randox Adiponectin has an extensive measuring range of 0.5-40µg/mL, which is vital for clinically accurate results. This ensures that low and high levels of adiponectin are detected within a sample, giving a more accurate assessment of T2DM risk.
C – Complementary Controls and Calibrators
Alongside our adiponectin reagent, we also have complementary controls and calibrators available, offering a complete testing package. Below are the details for our adiponectin controls and calibrators:
|Adiponectin Control Level 2||AO2801||3x1ml|
|Adiponectin Control Level 3||AO2802||3x1ml|
T – Time Consumption
Randox Adiponectin is an automated assay format, meaning that you save time in the laboratory and removes the inconvenience compared to traditional ELISA methods. In addition, when running ELISA methods, the risk of error and contamination is higher than automated methods, which can compromise clinical results.
I – Immunoturbidimetric (Latex Enhanced) method
Randox Adiponectin adopts a Latex Enhanced Immunoturbidimetric method which delivers high performance. This method works through measuring the absorbance of light, whereby inert microscopic particles enlarge the immune complexes, amplifying the reaction and significantly increasing the sensitivity of the reaction.
N – Normal weight
A normal body weight doesn’t mean you are not at risk of developing T2DM. Abdominal Visceral Fat (AVF) is stored deeper than subcutaneous fat and can be wrapped around the body’s major organs such as the liver. With higher levels of AVF inversely correlated with adiponectin levels, this makes adiponectin a strong predictor of T2DM risk and other pathologies such as metabolic syndrome, cancer and CVD.
Please contact us at email@example.com for more information.
Hot off the heels of its first ever Randox Health Grand National, global healthcare company Randox returned this weekend to Bushmills to again host its International Polo Tournament. Renowned polo players from across the world joined the founder of the Co Antrim-based firm, Dr Peter FitzGerald, to play in the coastal town.
Following a successful event last year, which was the first of its kind held in Northern Ireland, the 2017 Randox Polo hosted almost 450 guests, including Lord-Lieutenant of County Antrim, Mrs. Joan Christie OBE, and Mayor of the Causeway Coast and Glens Borough Council, Joan Baird, who delivered the match ball of the first polo game. Former Miss Northern Ireland and fitness blogger Tiffany Brien, added a touch of glamour to the event.
On display was the company’s latest venture – the Randox Health Mobile Clinic. The unveiling of the bespoke Mercedez-Benz vehicle marks a departure from traditional models of healthcare provision, as the company’s advanced health screening programmes are now available to people anywhere in the country, using its travelling team of trained scientists and phlebotomists.
It was a victory for the Randox team in their first game of the tournament, as they went head-to-head with Scotland, but it was the Republic of Ireland team who emerged winners of the International Polo Tournament when they scored more goals than Team Randox in the final match of the day.
Randox, a recognised supporter of the arts, launched the weekend with a performance from Camerata Ireland Cameratino, an ensemble composed of acclaimed Irish flautist Eimear McGeown, and a String Trio including Violinist Sarah Sew, Violist Nathan Sherman and Celloist Gerald Peregrine, in Dundarave Estate.
The musical element continued on Saturday with a Beating of the Retreat by the Royal Irish Regimental Band, including the highly popular “Highland Cathedral,” and a unique version of “Run” by Snow Patrol.
Local Bushmills residents weren’t put off by the wet conditions, and turned out to watch both the polo tournament, and the fireworks display which rounded off the event.
Randox Founder and Managing Director, Dr. Peter FitzGerald, a keen horseman who played in the polo tournament, commented;
“Given that our inaugural tournament in 2016 received such positive feedback from the Bushmills community, we are delighted to have been able to once again bring the event to the beautiful North Coast and its residents, and to bring the Randox Health message to our Polo guests. By prioritising your health and wellbeing you can make the most of life’s special moments and occasions – like this great polo tournament.
“We’re very lucky that the resilient spirits of the local Bushmills community weren’t dampened by the rain, and everyone was able to enjoy a wonderful afternoon together on the beautiful north coast.”
For more information about the Randox Polo Tournament in Bushmills contact the Randox PR team: Call 028 9442 2413 or email firstname.lastname@example.org